NCT03196622

Brief Summary

Identify the threshold which the handgrip strenght can be used as a screening test of sarcopenia. Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 21, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 23, 2017

Completed
18 days until next milestone

Study Start

First participant enrolled

July 11, 2017

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
Last Updated

July 27, 2017

Status Verified

June 1, 2017

Enrollment Period

1.4 years

First QC Date

June 21, 2017

Last Update Submit

July 25, 2017

Conditions

Sarcopenia

Keywords

SarcopeniaElderly peopleHospitalization

Outcome Measures

Primary Outcomes (1)

  • Handgrip test could be used as a screening test of sarcopenia

    at day 1

Study Arms (1)

Older people

EXPERIMENTAL

A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.

Device: Handgrip test

Interventions

Handgrip testDEVICE

Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.

Older people

Eligibility Criteria

Age75 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • ≥ 75 years old

You may not qualify if:

  • Palliative care,
  • Protection of vulnerable adults

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, Auvergne, 63003, France

RECRUITING

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Officials

  • Marie BLANQUET

    CHU de Clermont-Ferrand

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Patrick LACARIN

CONTACT

04 73 75 11 95placarin@chu-clermontferrand.fr

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Open
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 21, 2017

First Posted

June 23, 2017

Study Start

July 11, 2017

Primary Completion

December 1, 2018

Study Completion

June 1, 2019

Last Updated

July 27, 2017

Record last verified: 2017-06

Locations

FR(1)